Targeting genes previously linked to a predisposition towards cancer.
TruSight Cancer includes genes associated with both common (eg, breast, colorectal) and rare cancers. In addition, the set includes 284 SNPs found to correlate with cancer through genome-wide association studies (GWAS). Content selection was based on expert curation of the scientific literature and other high-quality resources.
The TruSight Cancer sequencing panel provides custom oligos targeting identified regions of interest. Sufficient product is supplied for four enrichment reactions. TruSight Cancer is compatible with TruSight Rapid Capture and is supported on the MiniSeq, MiSeq, NextSeq, and HiSeq sequencing systems.
6 human reference samples were prepared using the TruSight Cancer sequencing panel. These libraries were sequenced on the MiniSeq System using a high output kit at a 2 x 100 bp read length configuration with dual indexing. The total yield was 5.2 Gb with 95.8% of bases at or above Q30.
For Research Use Only.
Note regarding biomarker patents and other patents unique to specific uses of products:
Some genomic variants, including some nucleic acid sequences, and their use in specific applications may be protected by patents. Customers are advised to determine whether they are required to obtain licenses from the party that owns or controls such patents in order to use the product in customer's specific application.
|Description||Document Type||File Info|
|TruSight Cancer Gene List||product_file||EXCEL(< 1 MB)|
|TruSight Cancer||Data Sheet||PDF(< 1 MB)|
|TruSight Portfolio: New Possibilities for Next-Generation Sequencing||Data Sheet||PDF(< 1 MB)|
|Illumina VariantStudio Data Analysis Software||Data Sheet||PDF(2 MB)|
Catalog IDs: FC-121-0202, 20005612